MedTrace Logo

Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes

NCT01467141 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2017-02-23

No results posted yet for this study

Summary

This trial is conducted in Europe. The aim of this trial is to evaluate safety and efficacy in children with type 1 diabetes.

Conditions

Interventions

DRUG

insulin aspart

Injected s.c. (under the skin) three times a day

DRUG

human insulin

Injected s.c. (under the skin) 30 minutes before the meals

DRUG

isophane human insulin

May be administered s.c. (under the skin) in both treatment groups thrice daily

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
2 Years
Max Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-19
Primary Completion
2003-10-15
Completion
2003-10-15

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01467141 on ClinicalTrials.gov